Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
INTRODUCTION: Apremilast is approved for the treatment of psoriasis and psoriatic arthritis. However, data on the efficacy and safety of apremilast in clinical practice are limited. We assessed the real-world use and effectiveness of apremilast in patients with moderate to severe plaque psoriasis visiting dermatologist practices in Belgium, from the perspectives of the patient and the physician. METHODS: This prospective observational study enrolled adults aged 18 years or more initiating apremilast between 6 April 2017 and 30 June 2018, per Belgian reimbursement criteria. Primary outcome was... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
Springer Healthcare Communications
|
Schlagwörter: | Adolescent / Adult / Anti-Inflammatory Agents / Non-Steroidal / Belgium / Humans / Psoriasis / Quality of Life / Severity of Illness Index / Thalidomide / Treatment Outcome / Apremilast / Patient Benefit Index / Patient-reported outcomes |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28928849 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/263798 |